提高与乳腺癌相关的血栓形成的预测,使用前化学疗法的血液和凝血特征
Regan Bucciol1, Hannah Parente2, Yousra Tera1,3
1Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada.
概括
这项研究发现,PROTECHT模型最好地预测乳腺癌 (BC) 患者的静脉血栓栓塞 (VTE) 风险. 将特定的血细胞计数添加到这个模型中,可以进一步改善VTE风险评估.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 医学诊断 医学诊断 医学诊断
背景情况:
- 静脉血栓栓塞 (VTE) 风险评估模型 (RAMs) 在乳腺癌 (BC) 患者群体中的适用性是不确定的.
- 目前的RAMs需要对BC患者的VTE预测疗效进行评估.
研究的目的:
- 在BC患者中比较现有的VTE RAM的疗效.
- 调查是否有额外的血液学参数和血栓形成显微镜 (TEG) 增强了静脉瘤预测.
- 开发一个修改后的RAM,以改善BC.VTE风险分层.
主要方法:
- 试点研究涉及女性BC患者在化疗前.
- 使用多个RAM (Khorana,维也纳CATS,PROTECHT,COMPASS-CAT,新维也纳CATSCORE,MDACC CAT) 和高凝血状态进行VTE评估.
- 分析TEG和血液学参数;开发一个修改后的RAM.
主要成果:
- 在47名BC患者中,5名 (10.6%) 患有VTE.
- PROTECHT显示了最高的预测值 (AUC = 0.844),其次是维也纳CATS (AUC = 0.781).
- 将不成熟的粒细胞和红细胞计数纳入PROTECHT的预测得到了改善 (AUC = 0.856).
结论:
- 在BC患者中,PROTECHT模型对VTE风险预测有前途.
- 将特定的血液学参数添加到PROTECHT可能会提高其预测准确性.
- 建议对更大的队列进行进一步验证,以确认这些发现.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
546
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
546
01:24Disorders of Hemostasis
647
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
647
01:21Cancer Survival Analysis
301
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
301